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Abstract
Background: Bleomycin is poorly permeant but potent cytotoxic and radiosensitizing drug. The
aim of the study was to evaluate whether a physical drug delivery system – electroporation can
increase radiosensitising effect of bleomycin in vitro and in vivo.
Methods: LPB sarcoma cells and tumors were treated either with bleomycin, electroporation or
ionizing radiation, and combination of these treatments. In vitro, response to different treatments
was determined by colony forming assay, while in vivo, treatment effectiveness was determined by
local tumor control (TCD50). Time dependence of partial oxygen pressure in LPB tumors after
application of electric pulses was measured by electron paramagnetic oxyimetry.
Results: Electroporation of cells in vitro increased radiosensitising effect of bleomycin for 1.5 times,
in vivo radiation response of tumors was enhanced by 1.9 fold compared to response of tumors that
were irradiated only. Neither treatment of tumors with bleomycin nor application of electric pulses
only, affected radiation response of tumors. Application of electric pulses to the tumors induced
profound but transient reduction of tumor oxygenation. Although tumor oxygenation after
electroporation partially restored at the time of irradiation, it was still reduced at the level of
radiobiologically relevant hypoxia.
Conclusion: Our study shows that application of electric pulses to cells and tumors increases
radiosensitising effect of bleomycin. Furthermore, our results demonstrate that the
radiobiologically relevant hypoxia induced by electroporation of tumors did not counteract the
pronounced radiosensitising effect of electrochemotherapy with bleomycin.
Background
Bleomycin (BLM) is a glycopeptide antibiotic that is used
in treatment of variety of human neoplasms, particularly
lymphomas, squamous cell carcinoma and germ-cell
tumors [1,2]. New understandings of mechanisms of its
cytotoxicity have led to development of more potent and
toxic therapeutic analogues [1]. Besides cytotoxic, BLM
has also radiosensitising effect that was demonstrated in
cells, experimental tumors as well as in the clinic [3-8].
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Cytotoxicity of BLM once inside the cell is very high, but
limited due to the poor uptake into the cells, which was
shown to be receptor mediated endocytosis [9]. It has
been shown that electroporation, a physical method of
drug delivery into the cells and tissues, induces transient
permeabilization of the cell membrane, thus enabling
facilitated transport of BLM and other cytotoxic drugs like
cisplatin into the cells, resulting in their increased cytotox-
icity [10-12]. This combined treatment of chemothera-
peutic drugs with hampered transport through the cell
membrane and electroporation in vivo was termed electro-
chemotherapy (ECT). Its effectiveness in local tumor con-
trol was demonstrated in numerous animal tumor models
and in several clinical studies in cancer patients with dif-
ferent tumors, malignant melanoma, sarcomas and carci-
nomas [13-15]. In addition, it was demonstrated that
application of electric pulses to the tumor as well as nor-
mal tissues reduces blood flow and oxygenation [16-19].
The role of electroporation in radiosensitisation of tumors
with cisplatin has already been shown. It was demon-
strated that electroporation increased radiosensitising
effect of cisplatin in two murine tumor models; EAT carci-
noma and LPB sarcoma [20,21]. Feasibility of this
approach was shown also in human adenocarcinoma skin
metastases [22]. Furthermore, it was demonstrated that
electroporation is effective in potentiating antitumor
effectiveness of hypoxia-selective drug tirapazamine com-
bined with tumor irradiation [23].
The aim of this study was to demonstrate the feasibility of
this approach with another radiosensitising drug, BLM,
which has proven its high effectiveness in ECT protocol.
In addition, tumor oxygenation was measured after appli-
cation of electric pulses to the tumors in order to deter-
mine the impact of reduced oxygenation in tumors on
radiation response.
Methods
Cell line, tumors and animals
Murine sarcoma LPB cells, syngeneic to C57Bl/6 mice
were used in the experiments. The cells were grown in
Eagle minimum essential medium (EMEM) supple-
mented with 10% fetal calf serum (FCS) (Sigma, Chemi-
cal Co., St. Louis, MO, USA). Cells were routinely
subcultured twice per week and maintained in a humidi-
fied atmosphere with 5% CO2 at 37°C. Inbred C57Bl/6
mice were purchased from the Institute of Pathology, Uni-
versity of Ljubljana (Slovenia). Mice were maintained at
21°C with natural day/night light cycle in a conventional
animal colony. In the experiments mice of both sexes were
used and distributed evenly between the groups. The aver-
age weight of mice subjected to treatment protocol was 22
g for female and 25 g for male mice.
Solid subcutaneous tumors were induced dorsolaterally
by the injection of 1.3 × 106 viable tumor cells in EMEM
supplemented with 2% FCS prepared from cell culture in
vitro. The tumors reached approximately 40 mm3 in vol-
ume in 10–12 days. Then, the mice were marked, divided
randomly into experimental groups and subjected to spe-
cific experimental protocol. Treatment protocols were
approved by the Ministry of Agriculture, Forestry and
Food of the Republic of Slovenia No. 323-02-237/01, and
are in compliance with the standards required by the
UKCCCR guidelines.
Drug
A stock solution (3 mg/ml) of BLM (Blenoxane, Bristol
Myers Squibb Co., Princeton, NJ, USA) was prepared in
phosphate buffered saline. Final concentration of BLM
(0.28 µg/ml) was freshly prepared in EMEM before each
experiment in vitro. In vivo experiments were performed
using BLM at the dose of 0.5 mg/kg, which was daily pre-
pared in 0.9% NaCl solution.
Irradiation of cells and tumors
For irradiation an X-ray unit Darpac 2000 (Gulmay Med-
ical Ltd, Shepperton, UK), operated at 220 kV, 10 mA, and
with 0.55 mm Cu and 1.8 mm Al filtration was used. In
experiments in vitro, cells (1 × 106 cells/ml EMEM) were
irradiated in low attachment plates at a dose rate 2 Gy/
min with graded doses (2–8 Gy) and thereafter plated in
Petri dishes for colony forming assay. In experiments in
vivo, tumors were irradiated at a dose rate 2.1 Gy/min with
single graded doses (5–50 Gy). Mice were put into a
holder for 6 mice on the X-ray unit with the apertures for
the irradiation of the tumors; the rest of the body of the
mice was protected by lead block, and by the lead holder
for the mice. In the holders, mice were restrained, but not
anaesthetized during irradiation. To ensure uniform dose
distribution through the tumor volume, the tumors were
exposed to irradiation by two opposing treatment fields
through each of which 50% of the dose was delivered
[21].
Electrochemotherapy of cells and tumors
For electroporation, an electric pulse generator Jouan
GHT 1287 (St. Herblain, France) delivering 8 square wave
electric pulses of amplitude over distance ratio of 1200 V/
cm, duration 100 µs at 1 Hz was used. In experiments in
vitro  90 µl of cell suspension (2.2 × 107 cells/ml) was
mixed with 10 µl of BLM at a concentration of 0.28 µg/ml,
as described previously [20]. Briefly, one half of the mix-
ture was exposed to electric pulses and the other half
served as a control for BLM treatment alone. Thereafter
the cells were incubated for 5 min at room temperature in
low attachment plates, diluted and plated on Petri dishes
for colony forming assay. The survival of cells treated with
ECT was normalized to electroporation treatment alone.BMC Cancer 2005, 5:115 http://www.biomedcentral.com/1471-2407/5/115
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In in vivo experiments, ECT of tumors was performed as
described previously [20]. Briefly, 3 min after intravenous
injection of BLM (injection volume 150 µl), electric pulses
were applied to the tumors using plate electrodes with 8
mm distance between them. Electrodes were placed on
the skin overlying the tumor at the opposing margins and
electric pulses delivered in two sets of 4 pulses in opposed
directions by rotating the electrodes for 90°.
Study design in vitro
To determine whether electroporation increases radiosen-
sitising effect of BLM in vitro, LPB cells were exposed to
electric pulses in the presence of BLM and placed in low
attachment plates for 5 min. Thereafter, 1 ml of EMEM
was added and after additional 5 min cells were irradiated
and plated in Petri dishes (Figure 1A). The survival of cells
treated with different treatment combinations that
included irradiation, were normalized to the appropriate
control group, in order to demonstrate the interaction
between the treatments on cell's survival. Survival of cells
after electroporation and irradiation was normalized to
the effect of electroporation, survival of cells after combi-
nation of BLM and irradiation was normalized to the
effect of BLM, whereas when the cells were irradiated after
ECT, cell survival data were normalized to the effect of
ECT. All the data were pooled from 3 independent exper-
iments performed in triplicates. The effect of treatments
was assessed by comparison of IC90 values (drug concen-
tration required to reduce cell survival for 90%). Enhance-
ment factor (EF) was calculated on the basis IC90 values.
Study design in vivo
To determine whether application of electric pulses
increases radiosensitising effect of BLM, ECT was com-
bined with local tumor irradiation with 20 min interval
between the treatments (Figure 1B). Antitumor effective-
ness of ECT combined with irradiation was evaluated by
comparing the effects to single treatments or to the other
treatment combinations: control untreated tumors,
tumors treated with BLM, electroporation or irradiation
only, tumors treated by ECT, and tumors treated with
combination of BLM or electroporation and irradiation.
Tumors were irradiated with single doses (5, 10, 15, 20,
25, 30, 35, 40, 45, 50 Gy). Each experimental group con-
sisted of 3–7 mice and the data were pooled from 3 inde-
pendent experiments.
Assessment of tumor response
The tumor volume was determined by measuring three
orthogonal tumor diameters (e1, e2 and e3) with Vernier
calliper. Tumor volume was calculated by the formula V =
π × e1 × e2 × e3/6. Tumor regression and regrowth was fol-
lowed until the tumors grew up to 350 mm3, and then the
animals were sacrificed. If the tumors regressed after ther-
apy, animals were checked for the presence of the tumor
in the irradiation field at 4–5 day intervals up to 100 days.
The animals were considered cured if they were tumor free
at day 100. Radiation dose needed to control 50% of irra-
diated tumors (TCD50) was used to determine response of
tumors (included were 9–21 mice per irradiation dose).
Dose response curves were computed by the logit method
of analysis [24]. Enhancement factor (EF) was calculated
based on TCD50 values.
EPR oximetry measurements
EPR oximetry was used to measure partial oxygen pressure
(pO2) in normal muscle, subcutaneous tissue, untreated
LPB tumors as well as in the tumors subjected to electric
pulses, as described previously [25]. Briefly, EPR oximetry
is based on the fact that molecular oxygen is paramagnetic
with two unpaired electrons and has a very rapid relaxa-
tion rate. It provides an effective relaxation mechanism to
other paramagnetic species via Heisenberg spin exchange
interaction. Consequently, the presence of oxygen influ-
ences both, spin-spin and spin-lattice relaxation times of
the paramagnetic probe. Therefore, an increase in oxygen
concentration increases the EPR spectra line-width,
decreases the resolution of hyperfine structure, and
decreases the microwave power at which the saturation of
the EPR absorption lines occurs. All these parameters can
be measured by EPR. Therefore, 3 small crystals of the oxy-
gen sensitive paramagnetic probe lithium phtalocyanine
(LiPc, 15 – 40 µm in diameter) were inserted into tumor
(one in centre and one in periphery) and one in selected
normal tissue (subcutaneous tissue or skeletal muscle)
one day before the treatment. Immediately after the treat-
ment, the EPR spectra were recorded continuously for 60
min and thereafter at each selected time point for 15 min.
The mice were anaesthetized by intraperitoneal injection
of a mixture of Domitor (1.0 mg/kg body weight; Pfizer
GmbH, Karlsruhe, Germany) and 10% ketamine (75.0
mg/kg body weight; Veyx-Pharma GmbH, Schwarzen-
born, Germany). During the anesthesia, warm air was
used to keep the body temperature as close as possible to
37°C with variations of up to 0.5°C during single meas-
urement. The measurements were performed on Varian E-
9 EPR spectrometer, with a custom-made low frequency
microwave bridge operating at 1.1 GHz and an extended
loop resonator (11 mm in diameter), both designed by
Professor T. Walczak (Darmouth Medical School, Hano-
ver, NH). Typical spectrometer settings were: modulation
frequency, 100 kHz; modulation amplitude not more
than one-third of the peak-to-peak line-width, and scan
range, 2 mT. The line width of the EPR spectra reflects the
pO2, on the site of the paramagnetic probe and was deter-
mined from the calibration curve presented elsewhere, as
the changes in the EPR spectrum can be calibrated with
known concentration of oxygen [25].BMC Cancer 2005, 5:115 http://www.biomedcentral.com/1471-2407/5/115
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Statistical analysis
All data were tested for normality of distribution. The sta-
tistical differences between the treatment groups were
assessed by a t-test after one-way ANOVA was performed
and fulfilled. SigmaStat statistical software (SPSS inc.) was
used for statistical analysis. P levels of less than 0.05 were
taken as significant.
Results
Radiosensitisation of LPB cells in vitro
In order to determine the radiosensitising effect of BLM,
LPB cells exposed to BLM alone or ECT were irradiated
with graded X-ray doses up to 8 Gy (Figure 2). Exposure of
cells either to BLM, electroporation or ECT statistically sig-
nificantly increased radiation response of LPB cells.
Increase in radiation response was the lowest when the
cells were exposed to BLM (EF = 1.19), probably due to
low BLM concentration and a very short exposure time.
On the other hand, the radiosensitivity of LPB cells was
greatly enhanced when the cells were pretreated with ECT
(EF = 1.53). When cells were exposed to electric pulses
prior to irradiation the enhancement factor was 1.25.
Therefore, radiosensitising effect of ECT might not be due
to just increased BLM delivery into the cells by electropo-
ration, but also to radiosensitisation by electroporation of
cells (Figure 2). Surviving fraction of LPB cells after perti-
nent control treatments BLM alone, electric pulses alone
and ECT is presented in Table 1.
Radiosensitisaton of LPB tumors in vivo
Radiosensitising effect of ECT was evaluated also on sub-
cutaneous LPB tumors in mice. As endpoints for evalua-
tion of antitumor effectiveness were used tumor growth
delay and local tumor control (TCD50 assay). Neither
treatment of animals with BLM alone nor application of
electric pulses to the tumors prior to irradiation of tumors
had any effect on local tumor control, as observed by
TCD50 values (Table 2, Figure 3). However, ECT of tumors
Schematic illustration of the experimental setting for the in vitro (A) and in vivo (B) study Figure 1
Schematic illustration of the experimental setting for the in vitro (A) and in vivo (B) study.
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statistically significantly increased radiation response of
the tumors (Table 2, Figure 3). TCD50 value was reduced
from 23.1 Gy in mice that were treated with irradiation
only, to 12.4 Gy in mice that were treated with ECT prior
to irradiation. Since the enhancement factor was 1.9, it is
evident that electroporation of tumors significantly con-
tributed to radiosensitisation of tumors with BLM, specif-
ically because combined treatment of ECT with
irradiation was statistically significantly more effective
than treatment of tumors that were irradiated in combina-
tion with electroporation or BLM.
Antitumor effectiveness of pertinent control groups BLM
alone, electric pulses alone and ECT is shown in Table 1.
ECT of tumors had good antitumor effect and some of the
tumors were cured (8.7%). Treatment with BLM only or
application of electric pulses to the tumors had minimal
effect on tumor growth and no tumor cures were obtained
after either of the treatments.
Side effects associated with application of electric pulses
were instantaneous contractions of muscles located
beneath the site of treatment, which disappeared immedi-
ately after each pulse. Irradiation alone or combined with
BLM, electric pulses and ECT resulted in hair loss, but
none of the treatments induced skin desquamation.
Tissue oxygenation
In order to determine whether electroporation of tumors
can induce radiobiologically relevant hypoxia, that could
reduce radiosensitising effect of ECT, pO2 was measured
in the tumors after exposure to electric pulses. To deter-
mine whether reduction in tumor oxygenation is confined
to the electroporated area (tumor), pO2 was measured in
the same animal also in the normal tissues (skeletal mus-
cle, subcutaneous tissue) that were not exposed to electric
pulses. Application of electric pulses to the tumors statis-
tically significantly reduced pO2 in the tumors (Figure 4).
Five min after application of electric pulses to the tumors
pO2 was lowered in the centre of the tumors down by 75%
and in the periphery of the tumors down by 50%. Imme-
diately thereafter, tumors started to reoxygenate; however
6 h after electroporation the oxygen level was still at 70%
of pretreatment level and even after 24 h was not
completely restored (Figure 4). Specifically, at 20 min
after electroporation of the tumors, i.e.  at the time of
tumor irradiation, in the tumor centre as well as in the
tumor periphery there was still reduced tumor oxygena-
tion, at the level of radiobiologically relevant hypoxia (4.6
± 0.6, 6.1 ± 0.3, respectively). In normal tissues; skeletal
muscle and subcutaneous tissue pO2 was not affected by
application of electric pulses to the tumors (Figure 4). In
addition, pO2 was measured in untreated LPB tumors at
the same time points to evaluate the whether tumor
growth can affect tumor oxygenation. As shown on Figure
4, pO2 in untreated tumors did not change throughout the
24 h measurement.
Discussion
This study shows that application of electric pulses to cells
and tumors increases radiosensitising effect of BLM. As
already demonstrated, electroporation of tumors
increases BLM uptake into the tumor cells [10] and there-
fore this might be the principal mechanism of the
increased radiosensitivity. Furthermore, our results dem-
onstrate that the radiobiologically relevant hypoxia
induced by electroporation of tumors did not counteract
the pronounced radiosensitising effect of ECT.
Radiosensitising effect of BLM was demonstrated in many
in vitro and in vivo studies, as well as in clinical trials [3,5-
8,26,27]. Good potentiation of radiation response was
found in some in vitro studies, even without use of drug
delivery systems [4], which is in agreement with our
results. Although with different concentration of BLM and
Radiation survival curves of LPB cells Figure 2
Radiation survival curves of LPB cells exposed to differ-
ent irradiation doses only and to a combination with bleomy-
cin (BLM; 0.28 µg/ml), electroporation and 
electrochemotherapy (ECT). Cell survival was determined 
using colony forming assay. Values are AM ± SEM (n = 9).BMC Cancer 2005, 5:115 http://www.biomedcentral.com/1471-2407/5/115
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incubation time used, the potentiation of radiation
response was similar in the study of Leith et al and ours
(enhancement factor 1.25 and 1.19, respectively). In vivo
studies on mice demonstrated potentiation of radiation
response with BLM when it was given in high doses up to
100 mg/kg [5,6]. At these doses radiation response was
potentiated either after single irradiation dose or in
fractionated regime up to 1.23-fold [5,6,8]. Our results
showed that radiation response in vivo was not affected by
BLM. The discrepancy in the response between our and
other studies could be attributed to the much lower dose
of BLM (0.5 mg/kg), which was used in our study.
Electroporation is one of the drug delivery systems which
was shown to be effective in potentiation of BLM and
cisplatin cytotoxicity [14]. In vivo ECT of tumors in exper-
imental systems as well as in treatment of cancer patients
is feasible and effective for local tumor control [13,15]. In
this system low doses of drugs are needed, because elec-
troporation of tumors in vivo increases drug accumulation
in tumor cells from 2-fold for cisplatin and 4-fold for BLM
[10,11]. Drug doses needed for effective local tumor con-
trol in ECT protocol are so low that they have minimal or
no antitumor effectiveness without subsequent applica-
tion of electric pulses to the tumors.
In order to reduce drug dosage for effective radiosensitisa-
tion of tumors several drug delivery systems can be used.
Drug delivery systems, such as incorporation of the drug
into liposomes or other vehicles and local drug adminis-
tration were used to increase delivery of cisplatin to
tumors [28-31], however to our knowledge there is no
reports using drug delivery systems for in vivo radiosensi-
tisation of tumors with BLM. Combination of ECT with
cisplatin and irradiation has already been tested in cells,
tumors in mice and a patient. The results demonstrated
that ECT increased radiation response of cells and tumors,
and that the predominant underlying mechanism was
increased cisplatin accumulation in the cells of tumors
[20-22]. The potentiation of radiation response by ECT
with cisplatin was 1.4 compared to tumors that were
treated with combined cisplatin and irradiation
treatment, and 1.6 compared to tumors that were irradi-
ated only [20]. In the present study, the potentiation of
radiation response by ECT with BLM was 1.9 fold com-
pared to tumors that were irradiated only and those that
were concomitantly treated with BLM, since BLM only
had no radiosensitising effect at this low drug dose. As dis-
cussed in our previous studies on ECT with cisplatin and
irradiation, several mechanisms could be responsible for
potentiation of radiation response of ECT with BLM
[20,21].
Table 1: Surviving fraction of the cells in vitro, tumor doubling time and complete responses of the tumors treated with BLM, 
electroporation and ECT.
In vitro In vivo
Group n Sfa n DT (days)b CR (n)c
Control 911 6 2 . 3  ±  0 . 1 0
BLM 9 0.83 ± 0.03 17 4.4 ± 0.5 0
EPd 9 0.81 ± 0.02 13 4.9 ± 0.8 0
ECT 9 0.69 ± 0.03 23 19.6 ± 2.2 2
a Surviving fraction of LPB cells
b Tumor doubling time of the tumors that regrew after the treatment (AM ± SEM)
c Tumor cures were determined 100 days after the treatment
d Electroporation
Table 2: Comparison between tumor curability dose (TCD50), confidence interval (95%) and EF for irradiation alone (IR) or combined 
with electroporation (EP-IR), BLM (BLM-IR), and ECT (ECT-IR) of LPB sarcoma tumors.
Group TCD50 Confidence interval (95-%) EF
IR 23.1 22.6–23.6
EP-IR 22.1 21.7–22.7 1.0
BLM-IR 22.8 22.4–23.4 1.0
ECT-IR 12.4 11.9–13.0 1.9BMC Cancer 2005, 5:115 http://www.biomedcentral.com/1471-2407/5/115
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First, electroporation induces transient permeability of
cell membrane and therefore enables increased drug accu-
mulation in the cells. For BLM as well as for cisplatin it
was shown that electroporation of cells or tumors causes
increased drug accumulation in tumor cells in vitro as well
as in tumors [10,11,32]. Therefore, increased BLM accu-
mulation in the tumor cells may consequently result in
better radiosensitisation of cells and tumors.
Second, application of electric pulses to the tissues, either
normal tissues or tumors results in temporary, but revers-
ible reduction of tissue perfusion [16-19,23,33]. The effect
was more pronounced in tumors compared to normal tis-
sues, where it was shown that electroporation induced
profound reduction of tumor blood flow and reduced
tumor oxygenation [17-20,23]. In order to verify whether
this kind of electric pulses induce hypoxia also in LPB
tumor model, used in this study, tissue oxygenation was
measured. It was shown that electroporation of tumors
induced instant, but reversible tumor hypoxia, which was
not restored at the time of tumor irradiation. Since the
induced tumor hypoxia was radiobiologically relevant
[34] it could have an effect on tumor response to irradia-
tion. However, the curability of tumors treated with the
electroporation combined with tumor irradiation was the
same as the curability of tumors that were irradiated only.
In contrast, our results in vitro demonstrated that electro-
poration of cells enhanced radiation response. Therefore
some other mechanisms may affect the radiation response
of tumors. It is already known that reactive oxygen species
are formed after electroporation of the cells in vitro
[35,36]. Reactive oxygen species are known to contribute
to radiation damage to the cells. Indeed, we have observed
in this and previous studies that electroporation of cells in
vitro in normoxic conditions predisposed them to radia-
tion damage [20,21]. In vivo on solid tumors, the radia-
tion response was dependent on tumor type.
Electroporation enhanced radiation response in EAT car-
cinoma, but not in LPB sarcoma [20,21]. Therefore, in this
study, the observed radiation response of tumors that
were exposed to electric pulses could be ascribed to, both
radiobiologically relevant tumor hypoxia and induction
of reactive oxygen species, the effects that counteract each
other.
Consequently, in the case of ECT combined with irradia-
tion, the electroporation-induced generation of reactive
oxygen species in the tumor cells may additionally con-
tribute to DNA damage induced by BLM and irradiation.
Radiation dose response curves for local tumor control of  LPB sarcoma tumors Figure 3
Radiation dose response curves for local tumor con-
trol of LPB sarcoma tumors. Tumors were treated with 
electrochemotherapy (ECT) 20 min prior to irradiation or in 
different combinations of irradiation either with bleomycin 
(BLM) given intravenously (0.5 mg/kg), or with application of 
8 electric pulses to the tumors (electroporation – irradiation; 
EP-IR)). Groups consisted at least of 9 mice per irradiation 
dose.
Time dependence of partial oxygen pressure in normal tis- sues and LPB sarcoma tumors after application of electric  pulses to the tumors Figure 4
Time dependence of partial oxygen pressure in nor-
mal tissues and LPB sarcoma tumors after applica-
tion of electric pulses to the tumors. pO2 measured in 
untreated LPB tumors at the same time points is also shown. 
Partial oxygen pressure was measured by EPR oximetry. Val-
ues are AM ± SEM (n = 7–10).
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However, since the data on reactive oxygen species were
obtained on cells in vitro further studies in vivo are needed
to demonstrate the presence and role of reactive oxygen
species in tumors after electroporation. This question
could be addressed also by prolonging the interval
between the BLM or ECT and tumor irradiation, so as to
ensure restitution of the tumor oxygenation before tumor
irradiation is performed. Furthermore, this problem
might be evaluated also by using anti-oxidant drugs in
combination with electroporation and irradiation.
In conclusion, results of our study show that ECT with
BLM greatly increased radiation response of LPB tumors.
ECT is already used in treatment of patients with cutane-
ous and subcutaneous tumor nodules [13-15]. Recently,
clinically certified generators of electric pulses came on
the market. This will enable broader application of ECT in
the clinics, also in combination with radiotherapy.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
SK participated in the design of the study, performed the
experiments, and drafted the manuscript. MC participated
in design of the study and critically revised the
manuscript. AG participated in design of the study and
experiments. MS helped to draft the manuscript and par-
ticipated in analysis and interpretation of the data. GS
conceived the study, participated in design of the study
and coordination, and critically revised the draft.
Acknowledgements
This work was supported by the Ministry of Higher Education, Science and 
Technology of the Republic of Slovenia.
References
1. Chen J, Stubbe J: Bleomycins: towards better therapeutics.  Nat
Rev Cancer 2005, 5:102-112.
2. Haskell CH: Drugs used in cancer chemotherapy.  In Cancer
Treatment Edited by: Haskell CH. Philadelphia: Saunders WB;
1990:63-65. 
3. Djeridane M, Oudard S, Escoffre-Barbe M, Lacote-Thierry L, Desa-
blens B, Briere HJ, Dib M, Cassasus P, Ghandour C, Lamy T, Lejeune
F, Simon M, Traulle C, Vigier M, Maisonneuve H, Breiere J, Colonna
P, Andrieu JM: Treatment of patients with advanced or bulky
Hodgkin's disease with 12-week doxorubicin, bleomycin, vin-
blastine, and dacarbazine-like chemotherapy regimen fol-
lowed by extended-field full-dose radiotherapy.  Cancer 2002,
95:2169-2179.
4. Leith JT, Lee ES, Leite DV, Glicksman AS: Enhanced X ray sensi-
tivity of human colon tumour cells by combination of N-
methylformamide with chemotherapeutic agents.  Int J Radiat
Oncol Biol Phys 1986, 12:1423-1427.
5. Lelieveld P, Scoles MA, Brown JM, Phil D, Kallman RF: The effect of
treatment in fractionated schedules with the combination of
X-irradiation and six cytotoxic drugs on the RIF-1 tumour
and normal mouse skin.  Int J Radiat Oncol Biol Phys 1985,
11:111-121.
6. Molin J, Sogaard PE, Overgaard J: Experimental studies on the
radiation-modifying effect of bleomycin in malignant and
normal mouse tissue in vivo.  Cancer Treat Rep 1981, 65:583-589.
7. Smid L, Budihna M, Zakotnik B, Soba E, Strojan P, Fajdiga I, Zargi M,
Oblak I, Dremelj M, Lesnicar H: Postoperative concomitant irra-
diation and chemotherapy with mitomycin C and bleomycin
for advanced head-and-neck carcinoma.  Int J Radiat Oncol Biol
Phys 2003, 56:1055-1062.
8. Teicher BA, Herman TS, Holden SA: Combined modality therapy
with bleomycin, hyperthermia and radiation.  Cancer Res 1988,
48:6291-9297.
9. Pron G, Mahrour N, Orlowski S, Tounekti O, Poddevin B, Belehradek
JJr, Mir LM: Internalisation of the bleomycin molecules
responsible for bleomycin toxicity: a receptor-mediated
endocytosis mechanism.  Biochem Pharmacol 1999, 57:45-56.
10. Belehradek J Jr, Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM:
Electropermeabilisation of cells in tissues assessed by the
qualitative and quantitative electroloading of bleomycin.  Bio-
chem Biophys Acta 1994, 1190:155-163.
11. Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G:
Increased platinum accumulation in SA-1 tumour cells after
in vivo electrochemotherapy with cisplatin.  Br J Cancer 1999,
79:1386-1391.
12. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R: Tox-
icity of anticancer agents mediated by electroporation in
vitro.  AntiCancer Drugs 2000, 11:201-208.
13. Gothelf A, Mir LM, Gehl J: Electrochemotherapy: results of can-
cer treatment using enhanced delivery of bleomycin by
electroporation.  Cancer Treat Rev 2003, 29:371-387.
14. Mir LM: Therapeutic perspectives of in vivo cell
electropermeabilization.  Bioelectrochemistry 2001, 53:1-10.
15. Sersa G, Cemazar M, Rudolf Z: Electrochemotherapy: advan-
tages and drawbacks in treatment of cancer patients.  Cancer
Ther 2003, 1:133-142 [http://www.cancer-therapy.org/index.html].
16. Gehl J, Skovsgaard T, Mir LM: Vascular reactionts to in vivo elec-
troporation: characterization and consequences for drug
and gene delivery.  Biochem Biophys Acta 2002, 1569:51-58.
17. Sersa G, Cemazar M, Parkins CS, Chaplin DJ: Tumour blood flow
changes induced by application of electric pulses.  Eur J Cancer
1999, 35:672-677.
18. Sersa G, Cemazar M, Miklavcic D, Chaplin DJ: Tumour blood flow
modifying effect of electrochemotherapy with bleomycin.
Anticancer Res 1999, 19:4017-4022.
19. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, Coer A,
Swartz HM, Cemazar M: Reduced blood flow and oxygenation
in SA-1 tumours after electrochemotherapy with cisplatin.
Br J Cancer 2002, 87:1047-1054.
20. Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G: Electroporation
of LPB sarcoma cells in vitro and tumours in vivo increases
radiosensitizing effect of cisplatin.  Anticancer Res 2003,
23:275-282.
2 1 . S e r s a  G ,  K r a n j c  S ,  C e m a z a r  M :  Improvement of combined
modality therapy with cisplatin and radiation using electro-
poration of tumours.  Int J Radiat Oncol Biol Phys 2000,
46:1037-1041.
22. Sersa G, Cemazar M, Rudolf Z, Fras AP: Adenocarcinoma skin
metastases treated by electrochemotherapy with cisplatin
combined with radiation.  Radiol Oncol 1999, 33:291-296.
23. Maxim PG, Carson JJ, Ning S, Knox SJ, Boyer AL, Hsu CP, Benaron
DA, Walleczek J: Enhanced effectiveness of radiochemother-
apy with tirapazamine by local application of electric pulses
to tumours.  Radiat Res 2004, 162:185-193.
24. Okunief FP, Morgan D, Niemerko A, Suit HD: Radiation dose
response of human tumours.  Int J Radiat Oncol Biol Phys 1995,
32:1227-1237.
25. Sentjurc M, Cemazar M, Sersa G: EPR oximetry of tumours in
vivo  in cancer therapy.  Spectrochim Acta Part A 2004,
60:1379-1385.
26. Lin JC, Ho ES, Jan JS, Yang CH, Liu FS: High complete response
rate of concomitant chemoradiotherapy for locally
advanced squamous cell carcinoma of the uterine cervix.
Gynecol Oncol 1996, 61:101-108.
27. Tseng CJ, Chang CT, Lai CH, Soong YK, Hong JH, Tang SG, Hsueh S:
A randomized trial of concurrent chemoradiotherapy versus
radiotherapy in advanced carcinoma of the uterine cervix.
Gynecol Oncol 1997, 66:52-58.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2005, 5:115 http://www.biomedcentral.com/1471-2407/5/115
Page 9 of 9
(page number not for citation purposes)
28. Begg AC, Deurloo MJ, Kop W, Bartelink H: Improvement of com-
bined modality therapy with cisplatin and irradiation using
intratumoural drug administration in murine tumours.  Radi-
other Oncol 1994, 31:129-137.
29. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS,
Peters AM, Stewart JS: Pegylated liposome-encapsulated doxo-
rubicin and cisplatin enhance the effect of radiotherapy in a
tumour xenograft model.  Clin Cancer Res 2000, 6:4939-4949.
30. Ning S, Yu N, Brown DM, Kanekal S, Knox SJ: Radiosensitization
by intratumoural administration of cisplatin in a sustained-
release drug delivery system.  Radiother Oncol 1999, 50:215-223.
31. Yapp DT, Lloyd DK, Zhu J, Lehnert SM: The potentiation of the
effect of radiation treatment by intratumoural delivery of
cisplatin.  Int J Radiat Oncol Biol Phys 1998, 42:413-420.
32. Engstrom P, Salford LG, Persson BRR: Distribution of bleomycin
in a rat model.  In Electrochemotherapy, Electrogenetherapy, and
transdermal drug delivery Edited by: Jaroszeski MJ, Heller R, Gilbert R.
New Jersey: Humana Press; 2000. 
33. Gehl J, Geertsen PF: Efficient palliation of hemorrhaging malig-
nant melanoma skin metastases by electrochemotherapy.
Melanoma Res 2000, 10:585-589.
34. Molls M, Vaupel P: Blood perfusion and microenvironment of
human tumours.  Berlin: Springer-Verlag; 2000. 
35. Bonnafous P, Vernhes M, Teissie J, Gabriel B: The generation of
reactive-oxygen species associated with long-lasting pulse-
induced electropermeabilisation of mammalian cells is
based on a non-destructive alteration of the plasma
membrane.  Biochem Biophys Acta 1999, 1461:123-134.
36. Gabriel B, Teissie J: Spatial compartmentation and time reso-
lution of photooxidation of a cell membrane probe in elec-
tropermeabilized Chinese hamster ovary cells.  Eur J Biochem
1995, 228:710-718.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/5/115/pre
pub